About me
Dr. Gillian Woollett joined Samsung Bioepis in November 2021 as VP, Head Regulatory Strategy and Policy, US (SBUS), to stand up a U.S. presence for science-based regulatory strategy and policy in the leading global market for biologics. Previously, she was SVP and Principal Regulatory Scientist at Avalere Health and, prior to that, Chief Scientist and Administrator at Engel & Novitt, LLP. Dr. Woollett was VP of Science and Regulatory Affairs at BIO and AVP at PhRMA, where she worked on biosimilars policy. Dr. Woollett earned her B.A., M.A. in Biochemistry from the University of Cambridge, and her D.Phil. in Immunology from the University of Oxford. She was a post-doc at the University of Edinburgh and the Biomedical Research Institute.
